2018
DOI: 10.1002/cia2.12039
|View full text |Cite
|
Sign up to set email alerts
|

The lipoxygenase‐hepoxilin pathway is activated in cutaneous plaque lesions of psoriasis

Abstract: There is increasing evidence that hepoxilins are novel inflammatory mediators. In vitro studies have shown that hepoxilins cause the mobilization of intracellular calcium in human neutrophils, induce plasma leakage, and potently stimulate the chemotaxis of human neutrophils. In vivo, the hepoxilin pathway is activated in conditions with inflammation, for example, pathogen infection, psoriasis, and arthritis, and hepoxilins promote inflammatory hyperalgesia and allodynia. 1 The "hepox" comes from hydroxy-epoxy,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
14
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(15 citation statements)
references
References 20 publications
1
14
0
Order By: Relevance
“…Almost all the known genes involved in either generation of long chain ceramides, or their oxygenation were significantly upregulated in psoriatic lesions indicating that this pathway is highly active (Figure 9). This significantly expands on previous observations that 12R-LOX is upregulated in both lesional and non-lesional skin in psoriasis, showing the entire pathway is affected (21,22,39,40).…”
Section: Discussionsupporting
confidence: 87%
“…Almost all the known genes involved in either generation of long chain ceramides, or their oxygenation were significantly upregulated in psoriatic lesions indicating that this pathway is highly active (Figure 9). This significantly expands on previous observations that 12R-LOX is upregulated in both lesional and non-lesional skin in psoriasis, showing the entire pathway is affected (21,22,39,40).…”
Section: Discussionsupporting
confidence: 87%
“…Generally, psoriatic disease-related metabolomics studies aim to identify metabolic markers that can be used for Ps and/or PsA diagnosis. While a few studies have examined the metabolite profiles of patients with autoimmune diseases (ADs) [9,10], or immunemediated inflammatory diseases (IMIDs) with no emphasis on Ps or PsA specifically [11], the majority of studies included in this review sought to identify metabolites that were associated with Ps by investigating Ps patients in comparison to healthy volunteers [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. Other studies focused on identifying metabolite profiles in Ps patients and correlating them with different measurements of disease activity [13,19,22,28,32,33].…”
Section: The Biological Questionmentioning
confidence: 99%
“…Most studies included in our literature search were non-hypothesis driven and therefore employed an untargeted metabolomics approach [12,[14][15][16][19][20][21][22][23]25,26,[31][32][33]36,41,42]. However, there were several studies that analyzed specific metabolites using a targeted metabolomics approach [9,10,13,18,24,27,28,30,39,40]. Fewer studies exploited both ap-proaches to analyze different classes of metabolites [17,29,35], while a couple studies initially performed an untargeted discovery study followed by validation of the results in a targeted way [11,34].…”
Section: Experimental Designmentioning
confidence: 99%
See 2 more Smart Citations